Humana Inc. (NYSE:HUM) Insider Sells $948,930.78 in Stock

Humana Inc. (NYSE:HUM) insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Humana Trading Up 3.9 %

Shares of HUM stock opened at $262.47 on Monday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The company has a market cap of $31.60 billion, a price-to-earnings ratio of 23.25, a PEG ratio of 2.12 and a beta of 0.55. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $471.37. The firm has a fifty day moving average price of $272.60 and a 200-day moving average price of $313.45.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The business had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. As a group, equities analysts predict that Humana Inc. will post 16.14 earnings per share for the current year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a $0.885 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.35%. Humana’s dividend payout ratio (DPR) is presently 31.36%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of HUM. State Street Corp lifted its position in shares of Humana by 1.0% in the third quarter. State Street Corp now owns 5,357,420 shares of the insurance provider’s stock valued at $1,701,582,000 after acquiring an additional 53,272 shares in the last quarter. FMR LLC lifted its holdings in Humana by 23.4% in the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after purchasing an additional 643,291 shares in the last quarter. Pzena Investment Management LLC boosted its stake in Humana by 8.1% in the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock worth $793,830,000 after purchasing an additional 187,903 shares during the period. Davis Selected Advisers grew its holdings in Humana by 16.1% during the 2nd quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock valued at $863,640,000 after buying an additional 321,233 shares in the last quarter. Finally, Marshall Wace LLP raised its position in shares of Humana by 118.9% during the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock valued at $532,564,000 after buying an additional 774,085 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on HUM. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and upped their price objective for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. Royal Bank of Canada cut their target price on Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Wells Fargo & Company lowered their price target on Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $395.00 target price on shares of Humana in a research note on Tuesday, October 1st. Finally, Leerink Partnrs downgraded shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Twenty analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Humana has an average rating of “Hold” and an average target price of $300.50.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.